The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine. The Food and Drug Administration has ...
Flu vaccines. File photo dated 05/10/09 of a nurse preparing to give a patient a shot from a hypodermic needle, as pregnant women are among those being urged to get the flu vaccine in a major public ...
The Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent, the first four-strain (two influenza A strains + two influenza B strains), cell-culture-derived, inactivated seasonal ...
Novartis has become the first vaccine manufacturer to win approval in the US for a seasonal flu vaccine that does not rely on the use of fertilised chicken eggs for its production. Flucelvax is made ...
Dublin, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The "FLUCELVAX QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides ...
The US Food and Drug Administration (:FDA) recently approved Novartis’ (NVS) influenza virus vaccine, Flucelvax. Flucelvax is the first cell-culture-derived vaccine, for patients 18 years of age and ...
Novartis won FDA approval Tuesday for Flucelvax ®, the first cell-culture-derived seasonal flu vaccine to be approved in the U.S. The vaccine was approved for adults 18 years old and older. Flucelvax ...
The Food and Drug Administration has cleared Seqirus’ Flucelvax Quadrivalent, the company's cell-based quadrivalent influenza vaccine, for an expanded age indication for people two years of age and ...
Seqirus has some big plans for its cell-based flu vaccine in the U.S. this year, but that doesn't mean its ambitions for Flucelvax stop at the U.S. borders. And with a new vote in the EU, those ...
As a dangerous flu season unfolds in the U.S., flu vaccine specialist Seqirus grew sales 26% in the six months leading up to Dec. 31, driven by its portfolio shift to differentiated vaccines. Seqirus ...
The expanded approval was based on data from a phase 3 study that compared Flucelvax Quadrivalent to a US-licensed comparator quadrivalent influenza vaccine. The Food and Drug Administration has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results